ABSTRACT
PURPOSE: Our meta-analysis was undertaken to evaluate the efficacy and safety of nebivolol compared with other second-generation ß blockers for hypertensive patients. METHODS: We searched PubMed, the Cochrane Library, EMBASE, and Clinical Trials.gov databases for randomized controlled trials (RCTs). The efficacy endpoints included systolic blood pressure (SBP), diastolic blood pressure (DBP), reduction of SBP and DBP, heart rate (HR), and adverse events (AEs). FINDINGS: Eight RCTs with 1514 patients met the inclusion criteria. HR was significantly lower in patients receiving other second-generation ß blockers compared with patients receiving nebivolol. There was no difference the reduction of blood pressure (SBP and DBP) or the reduction of SBP or DBP between the groups. The incidence of AEs was lower in patients taking nebivolol compared with patients taking other second-generation ß blockers. CONCLUSIONS: No significant difference was demonstrated between nebivolol and other second-generation ß blockers in the reduction of blood pressure, SBP, and DBP. The tolerability of nebivolol was significantly better compared with other second-generation ß blockers, and nebivolol was also associated with a stable HR and a lower risk of AEs compared with other second-generation ß blockers.
